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Background: Celastrol is a promising anti-tumor agent, yet it also elevates heat shock proteins (HSPs), especially
HSP70, this effect believed to reduce its anti-tumor effects. Concurrent use of siRNA to increase celastrol’s anti-
tumor effects through HSP70 interference has been reported, but because siRNA technology is difficult to clinically
apply, an alternative way to curb unwanted HSP70 elevation caused by celastrol treatment is worth exploring.
Methods: In this work, we explore three alternative strategies to control HSP70 elevation: (1) Searching for cancer
cell types that show no HSP70 elevation in the presence of celastrol (thus recommending themselves as suitable
targets); (2) Modifying HSP70-inducing chemical groups, i.e.: the carboxyl group in celastrol; and (3) Using signaling
molecule inhibitors to specifically block HSP70 elevation while protecting and/or enhancing anti-tumor effects.
Results: The first strategy was unsuccessful since celastrol treatment increased HSP70 in all 7 of the cancer cell
types tested, this result related to HSF1 activation. The ubiquity of HSF1 expression in different cancer cells might
explain why celastrol has no cell-type limitation for HSP70 induction. The second strategy revealed that modification
of celastrol’s carboxyl group abolished its ability to elevate HSP70, but also abolished celastrol’s tumor inhibition
effects. In the third strategy, 11 inhibitors for 10 signaling proteins reportedly related to celastrol action were tested,
and five of these could reduce celastrol-caused HSP70 elevation. Among these, the peptide deformylase (PDF)
inhibitor, actinonin, could synergize celastrol’s proliferation inhibition.
Conclusions: Concurrent use of the chemical agent actinonin could reduce celastrol’s HSP70 elevation and also
enhance proliferation inhibition by celastrol. This combination presents a novel alternative to siRNA technology and
is worth further investigation for its potentially effective anti-tumor action.Background
Celastrol is a triterpenoid compound first identified in the
plant Tripterygium wilfordii Hook F (TWHF). This herb
has been used in China for many years to treat rheumatic
diseases. Celastrol is an active component with many ac-
tions, among which are anti-tumor effects. It has been
confirmed that celastrol can exert anti-tumor effects both
in vitro and in vivo towards a variety of tumor cells with
different tissue origins [1-3]. Celastrol’s anti-tumor effects* Correspondence: shanghai_zhang@hotmail.com
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unless otherwise stated.are related to this agent’s ability to arrest the cell cycle and
induce apoptosis [2-5].
In addition to its anti-tumor effects, celastrol also has
the capacity to trigger heat shock response (HSR), causing
the elevation of multiple kinds of heat shock proteins
(HSPs), especially HSP70, regarded as a hallmark of HSR.
Westerheide et al. demonstrated for the first time that
celastrol could induce HSPs in several cell lines and sug-
gested that it might be useful in treating neuron degenera-
tive diseases [6]. Following this research, several groups
confirmed that celastrol could indeed improve neuron de-
generative alterations [7-9]. For example, in the G93A
SOD1 transgenic mouse model of ALS, celastrol signifi-
cantly improved motor performance and delayed the onset
of ALS, in part by increasing HSP70 expression in thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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mice [7]. The mechanism for celastrol’s HSR induction is
suggested to be due to celastrol’s ability to inhibit HSP90,
in turn causing HSF1 release and activation.
Though celastrol’s HSR induction can be applied to
neuron degenerative disease management, for anti-tumor
applications, HSR induction is an unwanted response,
since the HSP elevation, especially HSP70 and HSP90, aid
tumor cell survival. Reducing HSR in celastrol-treated
tumor cells might enhance this agent’s anti-tumor effects.
This notion is supported by the findings of Matokanovic
et al., who recently proved that siRNA silencing of HSP70,
a prominent molecule in celastrol-caused HSR, enhances
celastrol-induced cancer cell death [10]. However, siRNA
technology requires transfection, and presently is difficult
to employ in clinical applications. As such, we consider
that an alternative method for controlling unwanted HSR
caused by celastrol is worth exploration in regards to
tumor treatment.
Theoretically, there are at least three strategies to
control unwanted HSR while preserving celastrol’s anti-
tumor effects. The first potential method is to find can-
cer cell types that do not undergo HSR in celastrol’s
presence, and then treat these kinds of tumors as most
suitable for celastrol application. As an example, it has
been suggested that some cell-type tumors, such as
MCF-7 (originating from breast cancer), have no HSR
when treated with celastrol [11]. A second potential
method is to modify celastrol’s chemical structure to
abolish HSR while maintaining anti-cancer ability. To
support this idea, some researchers have suggested that
the quinone methide moiety is critical to celastrol’s
cytotoxic and apoptotic activity, while the acidic carb-
oxylate group is important to heat shock response and
cytoprotective activity [6]. This means that modification
of celastrol’s carboxyl group might help us achieve our
goal. The third potential method is to modify cells to
control HSR signaling. For this strategy, we used
the knowledge that siRNA can down-regulate HSP70.
Since siRNA application presents clinical difficulties, we
thought that inhibitors targeting the signaling proteins
might block the HSR pathway and achieve the same
goal. These potential targets, however, are still under
investigation.
In this paper, we explore the above strategies in the
following ways; first, we observed celastrol’s effects on
HSR induction in tumors of different cell types. Second,
we evaluated the effects of modifying celastrol’s carboxyl
group on HSR induction and proliferation inhibition.
Third, we observed the effects of a panel of signaling
molecule inhibitors on these two celastrol actions. The
results showed that the peptide deformylase inhibitor,
actinonin, could reduce HSR while enhancing prolifera-
tion inhibition.Methods
Materials
RPMI 1640 medium, Dulbecco’s modified Eagle’s medium
(DMEM), fetal bovine serum (FBS), and streptomycin/
penicillin for cell culture were obtained from PAA Labo-
ratories (Linz, Austria). Wang resin was obtained from
Synthesis Technologies Inc. (Tianjin, China). DMAP, DCC
and DMF were purchased from Dikma Technologies Inc.
(Beijing, China). Fmoc-L-Gly-OH and HBTU came from
Tianmapharma Co., Ltd (Suzhou, China). Piperidine and
NMM were obtained from Sinopharm Chemical Reagent
Co., Ltd (Shanghai, China). Carboxyfluorescein diacetate,
succinimidyle ester (CFSE) was from Molecular Probe
(Eugene, OR) and 7-Amino-actinomycin D (7-AAD) was
purchased from Anaspec (San Jose, CA). Novobiocin (NB)
and dimethyl sulfoxide (DMSO) were purchased from
Sigma (St. Louis, MO). 17-allylamino-17- demethoxygel-
danamycin (17-AAG) was obtained from Invivogen (San
Diego, CA). Anti-HSF1 antibody (Cat. 4356) was obtained
from Cell Signaling Technology Inc. (Boston, MA). Anti-
HSP70, anti-HSP40, anti-HSP90, and anti-p-HSF1 (Ser326)
antibodies were purchased from ENZO Life Sciences Inc.
(Farmingdale, NY, USA). Anti-p-HSF1 (Ser303) was pur-
chased from Abcam (Cambridge, MA, US). Nuclear and
Cytoplasmic Protein Extraction Kit, BCA protein assay
reagent kit and Beyo ECL Plus for western blot were pur-
chased from Beyotime Biotechnology (Jiangsu, China).
Phosphatase inhibitor cocktail tablets were obtained from
Roche (Mannheim, Germany). All reagents were stored ac-
cording to manufacturer recommendations.
Celastrol was extracted as previously reported by us
[12]. Celastrol and 17-AAG were dissolved in 50 mM
and 1 mg/ml in DMSO, respectively. NB was dissolved
in ddH2O. All of these drugs were stored at -20°C and
used within 3 months of preparation. The stored solu-
tion was further diluted with RPMI 1640 medium or
DMEM to a proper lower concentration immediately be-
fore experiments.Cell culture and treatment
The seven kinds of human cancer cell lines used in this
study were obtained from the Shanghai Cell Bank of the
Chinese Academy of Sciences, including breast cancer cell
lines MCF-7 and MDA-MB-468, prostate cancer cell line
PC3, hepatic cancer cell line HepG2, leukemic cell lines
THP-1, U937, and NB4. Cells were maintained in RPMI
1640 or DMEM supplemented with 10% FBS, 100 IU/ml
penicillin and 100 μg/ml streptomycin in a humidified 5%
CO2 incubator at 37°C. Exponentially growing cells were
used for experiments. Cells were seeded into 96-well or
6-well culture plates followed by exposure to the indicated
doses of celastrol, 17-AAG, or NB for the indicated times.
The culture medium with DMSO (vehicle) served as
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0.1%. Each experiment was repeated at least three times.
Western blot
Cells were incubated in lysis buffer and cleared by centri-
fugation at 13,000 × g for 10 min. For the phosphorylation
protein assay, phosphatase inhibitor was added to sup-
press the activity of phosphatase. The extraction of cyto-
plasmic and nuclear protein was performed according to
product manufacturer instructions. A BCA protein assay
reagent kit determined protein concentrations. Aliquots of
samples were subjected to 10% SDS-polyacrylamide gels
and then transferred to polyvinylidenedifluoride (PVDF)
membranes. Membranes were probed with the indicated
antibodies. Detection was accomplished using correspond-
ing horseradish peroxidase (HRP)-conjugated secondary
antibodies followed by development with Beyo ECL Plus;
pictures were captured by G: BOX iChemi XR (Syngene
Inc., UK).
Immunofluorescence
Cellular localization of HSF1 was assessed by immuno-
fluorescence. PC3 monolayers grown on coverslips were
exposed to 600 nM of celastrol for 10 min. At the end of
the experimental period, PC3 monolayers were washed
twice in cold PBS and fixed with 2% paraformaldehyde for
20 minutes. After being permeabilized with 0.1% Triton
X-100 in PBS at room temperature for 20 minutes, mono-
layers were then incubated in blocking solution composed
of bovine serum albumin and normal donkey serum in
PBS for 1 hour. Cells were then labeled with primary anti-
bodies in blocking solution overnight at 4°C. After being
washed with PBS, the cells were incubated in Alxa Fluor
488 conjugated-secondary antibody for 1 hour at room
temperature. Before being mounted on microscope slides,
cells were incubated in PI at 37°C. Immunolocalization of
HSF1 protein was visualized using an Olympus fluores-
cence microscope (Tokyo, Japan).
Synthesizing structural analogues for celastrol
The celastrol analogue we used was celastrol attached to
tri-petite of cylcine, a structure with similar length but
less complicated than those used by Klaić et al to modify
celastrol [13]. It was synthesized as follows: Wang resin
was put into a tube and DMF (15 mg/ml) was added.
After shaking for 30 min, the solution was filtered out.
Then, Fmoc-L-Gly-OH, DMAP, DCC, and DMF were
added sequentially, after reaction with shaking for
30 min, acetic anhydride was added as a blocker. 20% pi-
peridine in DMF was used to remove the protective
group Fmoc, followed by successive washing with DMF,
methanol, and DMF, then, Fmoc-L-Gly-OH, HBTU and
NMM were added, and a condensation reaction was car-
ried out for 30 min, and the system was washed and20% piperidine in DMF used to remove the Fmoc group.
The system was washed again, and the condensation re-
action repeated until the third glycine was coupled.
Then, celastrol was added and connected to the tri-
peptide of glycine through another 30 min round of con-
densation reaction in the presence of HBTU and NMM.
The reaction system was washed as in previous steps
and additionally washed with DCM three times. The
resin was dried, and the synthesized product was cut
and purified with semi-preparative HPLC (SHIMADZU,
Japan). Celastrol analogues and tri-peptide alone were
identified by API 150EX Mass Spectrometer System (PE
Sciex Corp. USA).
Cell counting by flow cytometry (FCM)
At the end of the indicated time points, cells were col-
lected and the cells were enumerated. Accurate enumer-
ation was carried out by FCM based on a single-tube
platform with self-made cell-Beads as internal controls, a
method originally reported by Harrison et al. [14] and
modified by us [15]. Briefly, samples were collected
followed by the addition of a known number of self-made
CFSE-containing Cell-Beads. Before analysis by FACScali-
bur flow cytometer (Becton-Dickinson, CA), 7-AAD was
added with a final concentration of 1 μg/ml for separating
dead cells. The FL1 detector was used for discrimination
between Cell-Beads and tested cells. The FL3 detector was
used to discriminate vital cells from dead. 10,000 events
were detected. The number of vital (or dead) cells was cal-
culated using the following equation:
Number of vital deadð Þcells ¼ ½ number of vital deadð Þ cells detected=
number of Cell−BeadsdetectedÞ
number of Cell−Beads input
Drug interaction study
U937 cells were incubated with different doses of celas-
trol or the inhibitors for 24 h, and the number of vital,
dead, and total cells were counted by FCM. Dm value
(the median-effect dose or concentration) of each drug
was obtained using Calcusyn 2.0 software. According to
the Dm value, various concentrations of the single agents
and the combinations with a fixed constant ratio were
tested. The drug interaction study was analyzed with
Calcusyn 2.0 software.
Statistics
Data in this study are presented as mean ± SD. Student’s
t-test or One-way analysis of variance (ANOVA) was
used for statistical evaluation of significant differences
among the groups using SPSS statistics 17.0 software. A
value of P < 0.05 was considered to be statistical signifi-
cance. Experiments were repeated at least three times.
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Celastrol induced HSP70 and other HSPs expression in
multiple kinds of cancer cells, accompanied by
phosphorylation and nuclear accumulation of HSF1
For the first strategy, we selected 7 cancer cell types and
detected the expressions of HSPs in these cancer cell
lines when treated with 600 nM celastrol for 24 h. (This
dose was selected by pre-experimental screening, a
process that was also applied to HSP90 inhibitors 17-
AAG and NB). Western blot results showed that celas-
trol use resulted in significant up-regulation of HSP70
in all 7 of these cancer cell lines (Figure 1A). CelastrolFigure 1 The effects of celastrol on HSPs expression in cancer cells ac
were treated with 600 nM celastrol for 24 h. The culture medium with DM
harvested and total protein was isolated. The levels of HSPs (HSP70, HSP90
were treated with 600 nM of celastrol, 17-AAG, or NB for 24 h. WB detected
The cells were treated with 600 nM of celastrol, 17-AAG, or NB for 10 min.
was probed with anti-HSF1, and phosphorylated-HSF1 (s326 and s303) anti
The cells were treated with 600 nM of celastrol for 10 min. The proteins in
levels of HSF1. (E) Nuclear accumulation of HSF1 in PC3 cells. The cells wer
medium was replaced by one of 600 nM of celastrol for 10 min. HSF1 was
which mainly recognizes HSF1 in nuclei. DNA was stained with PI (red). The
17-allylamino-17- demethoxygeldanamycin; NB: novobiocin.treatment-caused HSP90 elevation was not found in 5 of
the 7 tested cell lines, excepting PC3 and NB4. Another
member of the HSP family, HSP40, was not significantly
affected by celastrol (Figure 1A).
The HSP90 inhibitor 17-AAG has been reported to in-
duce HSPs while another HSP90 inhibitor, NB, cannot
[16,17]; thus these two agents were chosen as positive
and negative agents to confirm the reliability of our ex-
perimental system. The effects of 17-AAG and NB in in-
ducing HSP70 were observed in these 7 cell lines. The
results showed that 17-AAG could significantly induce
HSP70 elevation, while NB could not (Figure 1B). Thesecompanied by HSF1 activation. (A) Seven kinds of cancer cell lines
SO (vehicle) served as control for drugs. After treatment, cells were
, and HSP40) were assayed by western blot (WB). (B) The cell lines
HSP70 expression. (C) Phosphorylation of HSF1 detected in PC3 cell.
The total protein was subjected to SDS-PAGE. The activation of HSF1
bodies. (D) Distribution of HSF1 in cytoplasm and nuclei in PC3 cells.
total cells, plasma, and nucleus were extracted and WB detected the
e grown on coverslips for at least 24 h in culture medium, then the
detected by immunofluorescence using an anti-HSF1 (green) antibody
magnification was ×1000. Con: control; Cel: celastrol; 17-AAG:
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ous reports on these two agents, indicating that our sys-
tem is reliable for evaluating celastrol’s ability to induce
HSP70.
The above results suggested that the induction of
HSPs, especially HSP70, is a common action of celas-
trol. That celastrol’s effects are not cancer cell type
dependent might be explained by another suggested ef-
fect of celastrol, HSF1 activation. HSF1 is ubiquitous
molecule in mammalian cells, and its activation could
cause HSP70 expression. Therefore, we observed the
effects of celastrol on HSF1 in PC3 cells. Western
blot analysis showed that celastrol treatment at 600 nM
for 10 min could significantly phosphorylate ser303
and ser326 on HSF1 when compared to the control
(Figure 1C). 17-AAG was also found to cause HSF1
phosphorylation, while NB did not. Then, we observed
the effects of celastrol on HSF1 distribution. The total
amounts of HSF1 were similar in both the DMSO-
treated control and celastrol-treated cells, however, a
reduction in cytoplasm and elevation in the nuclear ex-
tract of this protein were revealed in cells treated with
celastrol at 600 nM for 10 min (Figure 1D), implying
that some of the HSF1 was rapidly relocated from cyto-
plasm to nuclei after celastrol was loaded. Consistent
with this analysis, the antibody (Cat. 4356 from Cell
Signaling Technology Inc., specific to the nuclear form
of HSF1) presented more intensified nuclei staining
in cells treated by celastrol for 10 min, indicating celas-
trol’s nuclear accumulation of this transcript factor
(Figure 1E). Phosphorylation and cellular distribution
detections showed that celastrol rapidly activated HSF1
in our system.Modification of celastrol’s carboxyl group abolished its
HSP70 induction effects as well its proliferation inhibition
For the second strategy, we modified celastrol’s carboxyl
group (suggested to be responsible for HSP70 induction)
by attaching tri-peptide of glycine via peptide bond
formation (Figure 2A), and then observed the effects of
this modified celastrol on HSP70 induction and cellular
survival. The purity of celastrol analogues or tri-peptide
of glycine was over than 95% (Figure 2B). The results
showed the modified celastrol did not induce HSP70
and phosphorylate HSF1 (Figure 2C and D), but also
could not inhibit proliferation (Figure 2E). Since this at-
tached structure, when used alone, showed no effects on
cellular HSP70 levels, disability of the modified celastrol
to inhibit proliferation should not be due to the attached
tri-peptide of glycine (Figure 2C and D). We also tried
modifying celastrol’s carboxyl group by attaching one
glycine rather than tri-peptide of glycine, but the results
were the same (data not shown).Peptide deformylase inhibitor actinonin reduced HSP70
induction while synergizing celastrol’s proliferation
inhibition
In the third strategy, we tried to find signaling protein in-
hibitors that might specifically inhibit the HSP70 induc-
tion pathway but not interfere with celastrol’s proliferation
inhibition. 11 inhibitors towards 10 signaling molecules
were observed, including PI3K/AKT inhibitor wortmanin,
PKC inhibitor staurosporine, mTOR1/2 inhibitor KU-
0063794, JNK inhibitor SP600125, peptide deformylase
(PDF) inhibitor actinonin, MEK1/2 or MEK1 inhibitor
U1026 and PD98059, IKK inhibitor IKK-16, p38 MAPK
inhibitor SB203580, and JAK inhibitor AG490, NF-κB
inhibitor PDTC. 5 of the inhibitors significantly reduced
celastrol-induced HSP70: PI3K/AKT inhibitor, PKC in-
hibitor, mTOR1/2 inhibitor, JNK inhibitor, and PDF in-
hibitor. Among these, the PDF inhibitor, actinonin, had
the most obvious HSP70 reduction effect. NF-κB inhibitor
PDTC exerted an enhancing action on HSP70 induction.
The remaining 5 inhibitors had no significant effects on
celastrol-induced HSP70 (Figure 3).
To determine if the inhibitors that reduced HSP70 ex-
pression could enhance the proliferation inhibition
caused by celastrol, we observed the combinative effects
of celastrol and these inhibitors in U937 cells. The re-
sults showed that only the combination of actinonin and
celastrol had a synergetic action in proliferation inhibition
(based on combination index (CI) values <1) (Figure 4A).
The other four inhibitors (PI3K/AKT inhibitor, mTOR1/2
inhibitor, JNK inhibitor, and PKC inhibitor) reduced
HSP70 levels, but also antagonized celastrol’s proliferation
inhibition (CI value >1) (Figure 4A).
Next, we observed the relationship between the inhi-
bitors for HSP70 induction and HSF1 activation. When
treated with celastrol for 10 min, the phosphorylations of
AKT, mTOR and HSF1 in U937 cells were dramatically in-
creased. JNK phosphorylation was slightly elevated. The
inhibitors of PI3K/AKT, mTOR, JNK, PKC could reduce
AKT and mTOR phosphorylation (activations) caused
by celastrol, but had no obvious or elevating effect on p-
HSF1. Interestingly and strikingly, the PDF inhibitor, acti-
nonin, significantly enhanced celastrol-induced HSF1
phosphorylation (Figure 4B). This demonstrates that these
compatible HSP70 inhibitors worked downstream of HSF1
activation.
Discussion
In this work, we tried three strategies to get rid of the
unwanted HSR in celastrol’s anti-tumor application, and
found that the peptide deformylase inhibitor, actinonin,
reduced HSP70 while enhancing celastrol’s proliferation
inhibition.
Over a dozen reports [18-20] have confirmed the
Westerheide et al. assertion that celastrol could induce
Figure 2 The effects of celastrol carboxyl group modification on HSP70 induction. (A) Structure of celastrol and its modifications. The
circled point indicates the modification location. R1 represents one of the structures that used by Klaić et al. to create celastrol analogues, while
R2 is tri-peptide of glycine, the analogue used in this paper. (B) Identifications of (a) tri-peptide of glycine and (b) the celastrol analogue were
`performed by mass spectrum analysis. (C) Effects of the celastrol analogue on HSP70 expression and HSF1 phosphorylation. U937 cells were
treated with 600 nM of celastrol, GGG, Cel-GGG, 17-AAG, or NB for 24 h. For phosphorylation assay, cells were incubated with drugs for 10 min.
WB detected HSP70 and p-HSF1 (s303 and s326). (D) The histogram shows western blot band density statistics for part C. * represents P < 0.05 vs.
control. (E) Effect of the celastrol analogue on proliferation inhibition. Cells were treated with 600 nM of celastrol or its analogue for 24 h, and
cellular survival was analyzed by FCM according to our previous report. GGG: tri-peptide of glycine; Cel-GGG: celastrol joined with tri-peptide of
glycine through peptide formation.
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not increase HSP70, and this was in human breast can-
cer cell line MCF-7 [11]. Therefore, our first strategy to
avoid unwanted HSP70 induction in antitumor celastrol
application was to find some specific cancer cell types
showing no HSR in celastrol’s presence (cancer cells
of this type would be most suitable for celastrol applica-
tion). We chose 7 cancer cell lines of different tissue
origin, including MCF-7, as test cells to evaluate celas-
trol’s ability to induce HSPs. Each of the tested cell lines
showed HSP70 elevation when treated with celastrol.
Since the discrepancy between our MCF-7 results and
the Matts et al. report might be due to the differences in
the experimental systems, we verified our system’s reli-
ability in evaluating agent HSPs-inducing ability by carry-
ing out contemporaneous observation of the effects of 17-
AAG and NB. Because 17-AAG and NB are widelyaccepted as an HSP70 inducer and non-inducer, respect-
ively, they were chosen as positive and negative controls.
In our experimental system, 17-AAG showed strong
induction ability, while NB did not. These results also
agree with previous reports about 17-AAG and NB, and
acted to verify our system’s reliability.
We also explored the molecular mechanism for celastrol-
induced HSP70 expression, and found that celastrol could
activate HSF1. With the ubiquitous expression of HSF1 and
HSP90 in the different cells we tested, it is easy to under-
stand HSP70 induction as a general celastrol effect. Because
of this, it is hard to select specific cancer cell types without
celastrol-caused HSP70 elevation, and it stands to reason
that this first strategy is probably untenable.
Our second strategy was based on the suggestion that
celastrol’s carboxyl group is responsible for this agent’s
HSP70 induction [6]. We found that modification of the
Figure 3 The effect of molecular signaling inhibitors on celastrol’s HSP70 induction. After incubation with the indicated doses of inhibitors
for 1 h, U937 cells were treated with 600 nM of celastrol for 24 h. The HSP70 expressions were assayed by WB.
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inducing effects; however, the anti-tumor effects were also
abolished in modification. The modified celastrol’s inability
to act on tumors might be due to the structural analogue’s
inability to enter cells, but this possibility was ruled out by
a simultaneous test of a liposome agent with modified
celastrol. Hence, our second strategy to control HSP90
induction through structural modification was also fruitless.
We and others have reported that HSP70 induction and
proliferation inhibition were both related to celastrol’s
HSP90 inhibition [10,21]. Moreover, we recently used mo-
lecular docking to find the role of celastrol’s carboxyl group
in HSP90 binding, the result indicating a novel binding
pocket in HSP90 dimers for celastrol in which the carboxyl
group formed two salt bonds with HSP90’s residues (these
results will be published in another paper). This result
highlighted the importance of the carboxyl group and gave
explanation to our unsuccessful modification results.
With the first two strategies unsuccessful, we tried a third
method in which we found some inhibitors that could
specifically tune down celastrol’s HSP70-inducing arm
while not affecting or possibly enhancing the proliferation-
inhibition arm. Most of the inhibitors we used have been
reported as celastrol-activated [22-27]. We found the inhib-
itors toward PI3K, AKT, mTOR, and JNK could effectivelyreduce celastrol-caused HSP70 induction, however, these
inhibitors also caused reductions in celastrol’s proliferation
inhibition ability.
The PDF inhibitor, actinonin, not only reduced HSP70
expression, but also synergized celastrol’s proliferation in-
hibition. Actinonin is a streptomyces-derived antibiotic,
and in addition to inhibiting peptide deformylase, it was
also recently shown to interact with and inhibit aminopep-
tidase N (APN)/CD13 [28], meprin α [29], and MMP-2
[28]. It has been clinically tested as a new anti-bacterial
drug, and its antitumor effects have also attracted research
attention [30]. Actinonin’s mechanism for affecting celas-
trol’s action is not explained in this study.
We also found that the 5 inhibitors that could inhibit
celastrol-induced HSP70 elevation did not inhibit HSF1
phosphorylation, indicating that these inhibitors worked
downstream of HSF1 activation. The exact mechanism
for blocking HSP70 induction remains for further
investigation.
Nevertheless, our results discovered a novel and practical
alternative to siRNA technology in reducing celastrol-
caused HSP70 elevation and enhancing celastrol’s anti-
tumor effects. Since actinonin itself is an anti-tumor agent
[30], its combinative use with celastrol in anti-tumor
applications is suggested here.
Figure 4 The effects of some signaling inhibitors on proliferation inhibition and HSP70 induction-related molecules activations.
(A) Isobologram analysis for combined effects of celastrol and the inhibitors reducing celastrol’s HSP70 induction on proliferation inhibition.
U937 cells were incubated with different doses of celastrol or the inhibitors for 24 h, and the numbers of vital, dead, and total cells were counted
by FCM. Dm value (the median-effect dose or concentration) of each drug was obtained using Calcusyn 2.0 software. According to the Dm value,
various concentrations of single agents and agent combinations with a fixed constant ratio were tested. The isobologram analysis was analyzed
with Calcusyn 2.0 software. Combination index (CI) = 1 refers to additive effect, CI < 1 refers to synergism, and CI > 1 means antagonism. ED50,
ED75, and ED90 represent effective doses of 50%, 75%, and 90% inhibition, respectively. The values were shown as mean ± SD. * P < 0.05 vs. 1.
(B) Effects of inhibitors reducing celastrol’s HSP70 induction on the HSP70 regulation signaling pathway. U937 cells were pre-incubated with the
inhibitors for 1 h, followed by treatment with 600 nM celastrol for 10 min. Total proteins were extracted by lysis buffer with phosphorylation
inhibitor. WB assayed phosphorylated or total signaling molecules.
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In this work, we found that HSP70 induction might be a
general response of different cancer cells to celastrol treat-
ment, and thus it may be impractical if not impossible to
base celastrol application on a pick-and-choose strategy.
We also found that modification of celastrol’s carboxylgroup can control this agent’s HSP70 induction action, yet
celastrol’s anti-tumor effects were also prevented. Lastly, we
found co-use of celastrol and actinonin could reduce
unwanted HSP70 induction and enhance celastrol’s tumor
proliferation inhibition, and thus propose this novel method
as a way to enhance celastrol’s anti-tumor effects.
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